Monopar Therapeutics (NASDAQ:MNPR) Given Buy Rating at Chardan Capital

Key Points

• Monopar Therapeutics (NASDAQ:MNPR) received a "buy" rating from Chardan Capital, with a target price of $60.00, indicating a potential upside of 10.11% from its previous close.
• Multiple research firms, including BTIG and HC Wainwright, have also provided favorable ratings and higher price targets for the stock, leading to a consensus "buy" rating with an average target price of $71.75.
• The company's stock has shown significant volatility, with a 12-month trading range between $3.65 and $54.54, highlighting notable growth despite recent insider sales totaling over $1.7 million.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report)'s stock had its "buy" rating reissued by stock analysts at Chardan Capital in a report issued on Tuesday,Benzinga reports. They currently have a $60.00 target price on the stock. Chardan Capital's price target suggests a potential upside of 10.11% from the company's previous close.

Other equities research analysts have also issued reports about the stock. BTIG Research reiterated a "buy" rating and set a $87.00 target price on shares of Monopar Therapeutics in a research report on Monday. Oppenheimer assumed coverage on shares of Monopar Therapeutics in a report on Wednesday, September 3rd. They issued an "outperform" rating and a $77.00 price objective for the company. Wall Street Zen upgraded shares of Monopar Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. HC Wainwright assumed coverage on shares of Monopar Therapeutics in a report on Tuesday, August 26th. They issued a "buy" rating and a $70.00 price objective for the company. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $74.00 price objective on shares of Monopar Therapeutics in a report on Wednesday, August 27th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, Monopar Therapeutics currently has a consensus rating of "Buy" and an average target price of $71.75.

Monopar Therapeutics Trading Up 10.7%

Shares of NASDAQ:MNPR opened at $54.49 on Tuesday. The company has a 50 day moving average of $39.67 and a 200 day moving average of $37.11. The stock has a market cap of $336.20 million, a P/E ratio of -16.36 and a beta of 1.20. Monopar Therapeutics has a 12 month low of $3.65 and a 12 month high of $54.54.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.12. On average, equities analysts forecast that Monopar Therapeutics will post -1.65 earnings per share for the current fiscal year.

Insider Activity at Monopar Therapeutics

In related news, CEO Chandler Robinson sold 16,800 shares of the stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $40.00, for a total transaction of $672,000.00. Following the sale, the chief executive officer directly owned 73,472 shares of the company's stock, valued at approximately $2,938,880. This represents a 18.61% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Kim R. Tsuchimoto sold 8,904 shares of the firm's stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $40.00, for a total transaction of $356,160.00. Following the sale, the director directly owned 11,486 shares in the company, valued at approximately $459,440. The trade was a 43.67% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 42,504 shares of company stock valued at $1,700,160. 20.50% of the stock is owned by insiders.

Institutional Trading of Monopar Therapeutics

A number of institutional investors have recently made changes to their positions in MNPR. Point72 Asset Management L.P. purchased a new stake in shares of Monopar Therapeutics during the 4th quarter valued at about $3,694,000. Affinity Asset Advisors LLC purchased a new stake in shares of Monopar Therapeutics during the 1st quarter valued at about $2,257,000. Geode Capital Management LLC lifted its stake in shares of Monopar Therapeutics by 99.7% in the 2nd quarter. Geode Capital Management LLC now owns 96,919 shares of the company's stock worth $3,468,000 after purchasing an additional 48,379 shares during the period. Goldman Sachs Group Inc. bought a new position in shares of Monopar Therapeutics in the 1st quarter worth approximately $673,000. Finally, Jane Street Group LLC bought a new position in shares of Monopar Therapeutics in the 1st quarter worth approximately $377,000. Hedge funds and other institutional investors own 1.83% of the company's stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.